Dr. Mario Delgado
Biography & Research Background
Mario Delgado, PhD, is based at the Instituto de Parasitología y Biomedicina López-Neyra (IPBLN), CSIC, Spain. He extensively characterized VIP as a pleiotropic immunomodulator, demonstrating its anti-inflammatory properties in autoimmune disease models (rheumatoid arthritis, multiple sclerosis) and neuroprotective effects in Parkinson’s disease models by blocking microglial activation. His publications in Nature research compound and Frontiers in Immunology have been seminal in establishing VIP’s experimental potential in inflammation and neurodegeneration. Mario Delgado is being referenced as one of the leading scientists involved in the research and development of VIP (Vasoactive Intestinal Peptide). In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Mario Delgado is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Mario Delgado is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.